晴空
Lv44
440 积分
2022-12-09 加入
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
4小时前
待确认
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
4小时前
已完结
-
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study on the behalf of G2I and IFM
3天前
已完结
-
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
7天前
已完结
-
[Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)]
9天前
已完结
-
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
9天前
已完结
-
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
1个月前
已完结
-
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
1个月前
已完结
-
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma
1个月前
已完结
-
A formula to estimate the approximate surface area if height and weight be known. 1916
1个月前
已关闭